Profile - To The Moon

Ck88

Posts · 6Posts · 6
Following · 0Following · 0
Followers · 0Followers · 0

- Ck88Ck88
  ·2021-06-21
  T
  Next Market Crash: 2 Top Growth Stocks to Buy Right Now
  Don't wait to jump on this red-hot tech company and unstoppable dividend stock.
  Next Market Crash: 2 Top Growth Stocks to Buy Right Now
  87 Comment
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3582003575432543","uuid":"3582003575432543","gmtCreate":1618909761908,"gmtModify":1618909761908,"name":"Ck88","pinyin":"ck88","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":164282437,"gmtCreate":1624207876929,"gmtModify":1703830677081,"author":{"id":"3582003575432543","authorId":"3582003575432543","name":"Ck88","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582003575432543","authorIdStr":"3582003575432543"},"themes":[],"htmlText":"T","listText":"T","text":"T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164282437","repostId":"2144775875","repostType":4,"repost":{"id":"2144775875","pubTimestamp":1624024260,"share":"https://ttm.financial/m/news/2144775875?lang=&edition=fundamental","pubTime":"2021-06-18 21:51","market":"us","language":"en","title":"Next Market Crash: 2 Top Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2144775875","media":"Motley Fool","summary":"Don't wait to jump on this red-hot tech company and unstoppable dividend stock.","content":"<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.</p>\n<p>No matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.</p>\n<h2>1. <a href=\"https://laohu8.com/S/FB\">Facebook</a></h2>\n<p><b>Facebook</b> (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.</p>\n<p>Facebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.</p>\n<p>2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.</p>\n<p>Facebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.</p>\n<p>If you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.</p>\n<p>After nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, <a href=\"https://laohu8.com/S/AONE\">one</a> that can generate consistent growth and maximize your portfolio returns.</p>\n<h2>2. AbbVie</h2>\n<p>Healthcare stock <b>AbbVie</b> (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from <b>Abbott Laboratories </b>in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.</p>\n<p>Stocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.</p>\n<p>The biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.</p>\n<p>There's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.</p>\n<p>Case in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.</p>\n<p>It's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.</p>\n<p>AbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.</p>\n<p>If you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Next Market Crash: 2 Top Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNext Market Crash: 2 Top Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/06/18/next-market-crash-101-2-top-growth-stocks-to-buy-r/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144775875","content_text":"The state of the stock market in recent weeks hasn't been for the faint of heart. Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster.\nNo matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. To that end, let's take a look at two top stocks that can help your portfolio navigate the next market storm and provide meaningful sources of growth for years to come.\n1. Facebook\nFacebook (NASDAQ:FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. The popular FAANG stock has gained approximately 25% since the beginning of 2021, and is up an eye-popping 41% compared to the same time last year.\nFacebook continues to control a massive share of the social media industry. According to Statista, \"Facebook accounted for nearly 71.8% of all social media site visits in the United States in May 2021.\" The company's ever-increasing market share is also driving exponential balance sheet growth.\n2020 was just another strong year in the books for Facebook, during which its total revenues increased 22% and its net income rose 58%. But Facebook's financial performance in the first quarter of 2021 left these figures in the dust. The company reported that its revenues surged 48% year over year during the three-month period.\nFacebook's net income grew by an even higher percentage -- a whopping 94% from the year-ago stretch. In addition, Facebook reported that its \"daily active users\" (what it calls daily Facebook users) and \"daily active people\" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone.\nIf you're wondering whether it's too late to buy Facebook on account of its upside potential, the answer is a resounding no. Facebook has plenty of juice left in it for long-term investors. And analysts currently estimate that the company can consistently deliver more than 20% average annual earnings growth for at least the next five years.\nAfter nearly two decades in business, Facebook continues to expand its market share and reassert its dominance of the social media sphere. This is a premium stock you can hold onto through both market highs and lows, one that can generate consistent growth and maximize your portfolio returns.\n2. AbbVie\nHealthcare stock AbbVie (NYSE:ABBV) is another golden egg to have in your basket before the next market crash rolls around. AbbVie spun off from Abbott Laboratories in 2013, and its former parent company is a veteran member of the elite stock club known as Dividend Aristocrats.\nStocks that snag the title of Dividend Aristocrats must raise their dividend for 25 consecutive years, and Abbott has done so for nearly 50. As a spinoff of Abbott, AbbVie is also considered a member of the Dividend Aristocrat club. It yields a robust 4.5% for investors at the time of this writing.\nThe biggest concern some investors have about AbbVie is the looming loss of U.S. patent protection for its blockbuster drug Humira in 2023. Humira is an immunosuppressive drug used to treat a range of conditions from arthritis to Crohn's disease. It raked in more sales than any other drug in the entire world in 2020 -- amassing total net revenues just shy of $20 billion during the 12-month period.\nThere's no doubt that AbbVie's balance sheet will reflect the loss of Humira's patent exclusivity in the U.S. in a few years. We need only look to AbbVie's loss of patent exclusivity in Europe -- which largely took effect in October 2018 -- as an example of this.\nCase in point: International sales of Humira were down 14% in 2020, but still totaled nearly $4 billion. In short, heightened competition in the U.S. will certainly detract from Humira's sales come 2023, but that doesn't mean that sales of the drug can't still inject healthy growth into AbbVie's balance sheet over the long term.\nIt's also important to note that AbbVie has a rock-star portfolio of top-selling drugs besides Humira. These include plaque psoriasis drug Skyrizi, cancer drugs Imbruvica and Venclexta, and rheumatoid arthritis drug Rinvoq. Moreover, AbbVie's acquisition of Allergan last year ushered well-known product names like Botox into its portfolio of lucrative products.\nAbbVie's first-quarter 2021 revenues of $13 billion represented a huge 51% increase from the year-ago period. Breaking AbbVie's first-quarter performance down by its top business segments -- immunology, hematologic oncology, aesthetics (which includes Botox Cosmetic), and neuroscience (which includes Botox Therapeutic) -- these four divisions marked respective year-over-year revenue growth of 13%, 8%, 35%, and 100%.\nIf you're looking for steady portfolio growth and attractive dividend income to anchor your portfolio in the next market storm, AbbVie offers shareholders the unbeatable combination of both.","news_type":1},"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}